{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:37:32Z","timestamp":1795117052174,"version":"4.10.3"},"reference-count":58,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hepatic Oncology"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/20450923.2025.2567741","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:37:32Z","timestamp":1761208652000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Qualitative research to understand the patient experience with advanced and\/or metastatic hepatocellular carcinoma"],"prefix":"10.1080","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-9004","authenticated-orcid":false,"given":"Sally","family":"Lanar","sequence":"first","affiliation":[{"name":"Insights, Evidence, and Value, ICON plc","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Kefsi","sequence":"additional","affiliation":[{"name":"Early Development Oncology, Sanofi Global R&D","place":["Vitry, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1547-253X","authenticated-orcid":false,"given":"Maria","family":"Armaou","sequence":"additional","affiliation":[{"name":"Insights, Evidence, and Value, ICON plc","place":["Reading, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-1719","authenticated-orcid":false,"given":"Fallon","family":"Jones-Lemmons","sequence":"additional","affiliation":[{"name":"Insights, Evidence, and Value, ICON plc","place":["Raleigh, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3343-8960","authenticated-orcid":false,"given":"Marie","family":"de La Cruz","sequence":"additional","affiliation":[{"name":"Insights, Evidence, and Value, ICON plc","place":["Raleigh, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-7863","authenticated-orcid":false,"given":"Kelly","family":"Lipman","sequence":"additional","affiliation":[{"name":"Insights, Evidence, and Value, ICON plc","place":["Raleigh, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3160-5347","authenticated-orcid":false,"given":"Benoit","family":"Arnould","sequence":"additional","affiliation":[{"name":"Patient Informed Development & Health Value, Translation, Sanofi Global R&D","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8820-8822","authenticated-orcid":false,"given":"C\u00e9cile","family":"Gousset","sequence":"additional","affiliation":[{"name":"Patient Informed Development & Health Value, Translation, Sanofi Global R&D","place":["Gentilly, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-318193"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14964-1"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.04.043"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02745"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007122"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1081\/cnv-120018233"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1188\/04.CJON.393-399"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29080434"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001952"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112503"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i29.3870"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211031141"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003060"},{"key":"e_1_3_8_16_1","unstructured":"FDA. FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma. 2025. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-heparocellular-carcinoma"},{"key":"e_1_3_8_17_1","unstructured":"FDA. FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_430028"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.015"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15618129"},{"issue":"6","key":"e_1_3_8_21_1","first-page":"2770","article-title":"Adverse events of sorafenib in hepatocellular carcinoma treatment","volume":"12","author":"Pang Y","year":"2022","unstructured":"Pang Y, Eresen A, Zhang Z, et al. Adverse events of sorafenib in hepatocellular carcinoma treatment. Am J Cancer Res. 2022;12(6):2770\u20132782.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1515\/oncologie-2023-0412"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac128"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32313"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00603.x"},{"key":"e_1_3_8_26_1","unstructured":"FDA. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. [2024; cited 2024 Sep 25]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims."},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0000000000000108"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02903-4"},{"key":"e_1_3_8_29_1","volume-title":"When a cure isn\u2019t possible: An interpretative phenomenological analysis of living with terminal hepatocellular carcinoma","author":"Sessions LL.","year":"2011","unstructured":"Sessions LL. When a cure isn\u2019t possible: An interpretative phenomenological analysis of living with terminal hepatocellular carcinoma. Saint Louis University; 2011. https:\/\/www.proquest.com\/openview\/cd03ab5d0afe42c3fae96881eb73a852\/1"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02939-1"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000315"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0000000000000188"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2039-5"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32834ec184"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-018-0536-7"},{"key":"e_1_3_8_36_1","first-page":"1564","volume-title":"Transplantation proceedings","author":"Gangeri L","unstructured":"Gangeri L, Bosisio M, Brunelli C, et al. Phenomenology and emotional impact of neuropsychiatric symptoms in orthotopic liver transplant for hepatocellular carcinoma. In Transplantation proceedings. 2007;39(5):1564\u20131568. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0041134507003211."},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523"},{"key":"e_1_3_8_38_1","unstructured":"Verbi Software. MAXQDA 2022. Berlin; 2021. https:\/\/www.maxqda.com\/"},{"key":"e_1_3_8_39_1","unstructured":"Joffe H Yardley L. Content and thematic analysis. In Marks David F. and Yardley Lucy editors. Research Methods for Clinical and Health Psychology. SAGE Publications; 2003:56\u201368."},{"key":"e_1_3_8_40_1","unstructured":"FDA. Patient-reported outcome measures: use in medical product development to support labeling claims. [2009; cited 2024 Dec 1]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims."},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.10.30"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1188\/17.ONF.562-570"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2013.14.8.4655"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2012.12.001"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnss.2023.09.009"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13672"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1742395318803668"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10101973"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-134"},{"key":"e_1_3_8_50_1","volume-title":"Systematic and other reviews: Criteria and complexities","author":"Sataloff RT","year":"2021","unstructured":"Sataloff RT, Bush ML, Chandra R, et al. Systematic and other reviews: Criteria and complexities. Los Angeles (CA): SAGE Publications Sage CA; 2021."},{"key":"e_1_3_8_51_1","unstructured":"FDA. Patient-focused drug development: Methods to identify what is important to patients -guidance for industry food and drug administration staff and other stakeholders. 2022."},{"key":"e_1_3_8_52_1","unstructured":"FDA. Patient-focused drug development: selecting developing or modifying fit-for-purpose clinical outcome assessments. 2022. htpps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1170"},{"key":"e_1_3_9_2_1","unstructured":"Of interest \u2013 Overview of immune ICI (checkpoint inhibitors) therapy and adverse effects."},{"key":"e_1_3_9_3_1","unstructured":"Of interest \u2013 Scoping review showing that qualitative studies were able to identify symptoms that were not routinely assessed with structured questionnaires."},{"key":"e_1_3_9_4_1","unstructured":"Of Interest \u2013 Guidance describing how the Food and Drug Administration (FDA) reviews and evaluates patient-reported outcome (PRO) instruments that are used to support claims in approved medical product labelling."},{"key":"e_1_3_9_5_1","unstructured":"Of significant interest \u2013 Development of a conceptual model of HCC symptoms and impacts."},{"key":"e_1_3_9_6_1","unstructured":"Of significant interest \u2013 Description of a patient journey map illustrating symptoms and impacts of HCC across different stages of severity."},{"key":"e_1_3_9_7_1","unstructured":"Of interest \u2013 Description of key qualitative themes related to HCC patients\u2019 quality of life."}],"container-title":["Hepatic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20450923.2025.2567741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:57:29Z","timestamp":1765461449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20450923.2025.2567741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/20450923.2025.2567741"],"URL":"https:\/\/doi.org\/10.1080\/20450923.2025.2567741","relation":{},"ISSN":["2045-0923","2045-0931"],"issn-type":[{"value":"2045-0923","type":"print"},{"value":"2045-0931","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ihep20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ihep20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2567741"}}